JP2024531799A - 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 - Google Patents

骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 Download PDF

Info

Publication number
JP2024531799A
JP2024531799A JP2024517163A JP2024517163A JP2024531799A JP 2024531799 A JP2024531799 A JP 2024531799A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024517163 A JP2024517163 A JP 2024517163A JP 2024531799 A JP2024531799 A JP 2024531799A
Authority
JP
Japan
Prior art keywords
effective amount
decitabine
cedazuridine
months
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024517163A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023049731A5 (https=
JP2024531799A5 (https=
Inventor
キール，ハロルド
アザブ，モハメッド
ハオ，ヨング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2024531799A publication Critical patent/JP2024531799A/ja
Publication of JPWO2023049731A5 publication Critical patent/JPWO2023049731A5/ja
Publication of JP2024531799A5 publication Critical patent/JP2024531799A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024517163A 2021-09-21 2022-09-21 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法 Pending JP2024531799A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163246547P 2021-09-21 2021-09-21
US63/246,547 2021-09-21
PCT/US2022/076757 WO2023049731A2 (en) 2021-09-21 2022-09-21 Methods of treating myelodysplastic syndromes with decitabine and cedazuridine

Publications (3)

Publication Number Publication Date
JP2024531799A true JP2024531799A (ja) 2024-08-29
JPWO2023049731A5 JPWO2023049731A5 (https=) 2025-09-30
JP2024531799A5 JP2024531799A5 (https=) 2025-09-30

Family

ID=85721229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024517163A Pending JP2024531799A (ja) 2021-09-21 2022-09-21 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法

Country Status (10)

Country Link
US (1) US20250000888A1 (https=)
EP (1) EP4404940A4 (https=)
JP (1) JP2024531799A (https=)
KR (1) KR20240064656A (https=)
CN (1) CN118201622A (https=)
AU (1) AU2022348907A1 (https=)
CA (1) CA3232623A1 (https=)
MX (1) MX2024003537A (https=)
TW (1) TW202327625A (https=)
WO (1) WO2023049731A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4704834A1 (en) * 2023-05-02 2026-03-11 Taiho Pharmaceutical Co., Ltd. Response-based dosing for treating cancer with a hypomethylating agent and cedazuridine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
WO2016085876A1 (en) * 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
JP2023504515A (ja) * 2019-12-05 2023-02-03 スミトモ ファーマ オンコロジー， インコーポレイテッド 骨髄異形成症候群の処置のための併用療法
JP2023510393A (ja) * 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
PH12022552250A1 (en) * 2020-02-25 2023-11-13 Otsuka Pharma Co Ltd Combination decitabine and cedazuridine solid oral dosage forms

Also Published As

Publication number Publication date
AU2022348907A1 (en) 2024-04-11
WO2023049731A2 (en) 2023-03-30
WO2023049731A3 (en) 2023-05-04
EP4404940A2 (en) 2024-07-31
US20250000888A1 (en) 2025-01-02
CA3232623A1 (en) 2023-03-30
TW202327625A (zh) 2023-07-16
CN118201622A (zh) 2024-06-14
MX2024003537A (es) 2024-05-03
EP4404940A4 (en) 2025-07-30
KR20240064656A (ko) 2024-05-13

Similar Documents

Publication Publication Date Title
TWI729492B (zh) 使用包含微脂體伊立替康（ｉｒｉｎｏｔｅｃａｎ）的組合療法治療胰臟癌的方法
Marty et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation
EP2755648B1 (en) Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP3964205A1 (en) Treatment or prevention of cardiovascular events
CN114727996A (zh) 用于治疗白血病或骨髓增生异常综合征的与维奈托克、吉瑞替尼、米哚妥林或其他化合物组合的阿扎胞苷
JP7742841B2 (ja) デシタビンとセダズリジンとの組み合わせの固形経口剤形
US20110243933A1 (en) Perifosine and Capecitabine as a Combined Treatment for Cancer
WO2023201338A1 (en) Combination therapy comprising a mat2a inhibitor and a parp inhibitor
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
JP2024531799A (ja) 骨髄異形成症候群をデシタビン及びセダズリジンを用いて処置する方法
WO2013086002A1 (en) Compositions, process of preparation of said compositions and method of treating cancer
CN112402432A (zh) 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法
JP2025509278A (ja) 小細胞肺癌を治療する方法
JP2005513167A (ja) エポシロン誘導体と代謝拮抗剤からなる組合せ
CN114728003B (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
IL292882A (en) Dosage of Bruton's tyrosine kinase inhibitor
US20230019186A1 (en) Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
HK40105549A (zh) 用地西他滨和西达尿苷治疗骨髓增生异常综合症的方法
JP2023548303A (ja) 癌を処置する為の医薬組成物及びその使用方法
EP3200879B1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii
Pacifici Clinical pharmacology of fluconazole in infants and children
WO2023177894A1 (en) Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
Standard et al. PrPemetrexed Disodium for Injection
EP4444303A1 (en) Combination therapy comprising a pkc inhibitor and a c-met inhibitor

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250919